22P HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Beatriz Rojas(Centro Oncológico de Galicia), Á.J. Díaz Bermejo(Research Institute Hospital 12 de Octubre), Valentina Boni, Cristian Dumay Hernández García(Research Institute Hospital 12 de Octubre), A Castelo(Research Institute Hospital 12 de Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Mario Martínez-López(Hospital Universitario 12 De Octubre), A.M. Castro Luna(HM Hospitales), Raquel Bratos(MD Anderson Cancer Center Madrid), M. Luisa Marín(Universidad Complutense de Madrid), E. Bernal Hertfelder(Research Institute Hospital 12 de Octubre), Estela Vega(HM Hospitales), Pablo Tolosa(Research Institute Hospital 12 de Octubre)
Cited by 13
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268